{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:49:44Z","timestamp":1791924584423,"version":"4.3.4"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s11883-023-01175-2","type":"journal-article","created":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T02:02:29Z","timestamp":1703037749000},"page":"921-929","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["How to Handle Elevated Triglycerides: Life after PROMINENT"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2948-6257","authenticated-orcid":false,"given":"Angela","family":"Pirillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7593-2094","authenticated-orcid":false,"given":"Alberico L.","family":"Catapano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,20]]},"reference":[{"issue":"32","key":"1175_CR1","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459\u201372. https:\/\/doi.org\/10.1093\/eurheartj\/ehx144.","journal-title":"Eur Heart J."},{"issue":"47","key":"1175_CR2","doi-asserted-by":"publisher","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","volume":"42","author":"HN Ginsberg","year":"2021","unstructured":"Ginsberg HN, Packard CJ, Chapman MJ, et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies \u2013 a consensus statement from the European Atherosclerosis Society. Eur Heart J. 2021;42(47):4791\u2013806. https:\/\/doi.org\/10.1093\/eurheartj\/ehab551. This statement from the European Atherosclerosis Society provides new evidence on the pathophysiological role of triglycerides and triglyceride-rich lipoprotein in atherosclerotic cardiovascular disease.","journal-title":"Eur Heart J."},{"issue":"4","key":"1175_CR3","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.106.637793","volume":"115","author":"N Sarwar","year":"2007","unstructured":"Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2007;115(4):450\u20138.","journal-title":"Circulation"},{"issue":"15","key":"1175_CR4","doi-asserted-by":"publisher","first-page":"e008740","DOI":"10.1161\/JAHA.118.008740","volume":"7","author":"PP Toth","year":"2018","unstructured":"Toth PP, Granowitz C, Hull M, Liassou D, Anderson A, Philip S. High triglycerides are associated with increased cardiovascular events, medical costs, and resource use: a real-world administrative claims analysis of statin-treated patients with high residual cardiovascular risk. J Am Heart Assoc. 2018;7(15):e008740. https:\/\/doi.org\/10.1161\/JAHA.118.008740.","journal-title":"J Am Heart Assoc."},{"issue":"19","key":"1175_CR5","doi-asserted-by":"publisher","first-page":"e015801","DOI":"10.1161\/JAHA.119.015801","volume":"9","author":"M Arca","year":"2020","unstructured":"Arca M, Veronesi C, D'Erasmo L, et al. Association of hypertriglyceridemia with all-cause mortality and atherosclerotic cardiovascular events in a low-risk Italian population: the TG-REAL retrospective cohort analysis. J Am Heart Assoc. 2020;9(19):e015801. https:\/\/doi.org\/10.1161\/JAHA.119.015801.","journal-title":"J Am Heart Assoc."},{"issue":"5","key":"1175_CR6","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.jacl.2019.07.004","volume":"13","author":"BC Case","year":"2019","unstructured":"Case BC, Bress AP, Kolm P, et al. The economic burden of hypertriglyceridemia among US adults with diabetes or atherosclerotic cardiovascular disease on statin therapy. J Clin Lipidol. 2019;13(5):754\u201361. https:\/\/doi.org\/10.1016\/j.jacl.2019.07.004.","journal-title":"J Clin Lipidol."},{"issue":"4","key":"1175_CR7","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/joim.13016","volume":"287","author":"A Baass","year":"2020","unstructured":"Baass A, Paquette M, Bernard S, Hegele RA. Familial chylomicronemia syndrome: an under-recognized cause of severe hypertriglyceridaemia. J Intern Med. 2020;287(4):340\u20138. https:\/\/doi.org\/10.1111\/joim.13016.","journal-title":"J Intern Med."},{"issue":"9","key":"1175_CR8","doi-asserted-by":"publisher","first-page":"e373","DOI":"10.1161\/ATVBAHA.123.319297","volume":"43","author":"EP Navarese","year":"2023","unstructured":"Navarese EP, Vine D, Proctor S, et al. Independent causal effect of remnant cholesterol on atherosclerotic cardiovascular outcomes: a Mendelian randomization study. Arterioscler Thromb Vasc Biol. 2023;43(9):e373\u201380. https:\/\/doi.org\/10.1161\/ATVBAHA.123.319297.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"34","key":"1175_CR9","doi-asserted-by":"publisher","first-page":"3258","DOI":"10.1093\/eurheartj\/ehab705","volume":"43","author":"BN Wadstrom","year":"2022","unstructured":"Wadstrom BN, Wulff AB, Pedersen KM, Jensen GB, Nordestgaard BG. Elevated remnant cholesterol increases the risk of peripheral artery disease, myocardial infarction, and ischaemic stroke: a cohort-based study. Eur Heart J. 2022;43(34):3258\u201369. https:\/\/doi.org\/10.1093\/eurheartj\/ehab705.","journal-title":"Eur Heart J"},{"issue":"1","key":"1175_CR10","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/joim.13059","volume":"288","author":"A Langsted","year":"2020","unstructured":"Langsted A, Madsen CM, Nordestgaard BG. Contribution of remnant cholesterol to cardiovascular risk. J Intern Med. 2020;288(1):116\u201327. https:\/\/doi.org\/10.1111\/joim.13059.","journal-title":"J Intern Med."},{"issue":"4","key":"1175_CR11","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","volume":"61","author":"A Varbo","year":"2013","unstructured":"Varbo A, Benn M, Tybjaerg-Hansen A, Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013;61(4):427\u201336. https:\/\/doi.org\/10.1016\/j.jacc.2012.08.1026.","journal-title":"J Am Coll Cardiol."},{"issue":"3","key":"1175_CR12","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1007\/s13340-023-00634-0","volume":"14","author":"T Hirano","year":"2023","unstructured":"Hirano T. Hypertriglyceridemia contributes significantly to high prevalence of small dense LDL-cholesterol in patients with type 2 diabetes, even when LDL-C targets are achieved. Diabetol Int. 2023;14(3):288\u201393. https:\/\/doi.org\/10.1007\/s13340-023-00634-0.","journal-title":"Diabetol Int."},{"issue":"5","key":"1175_CR13","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1161\/ATVBAHA.114.303284","volume":"34","author":"RC Hoogeveen","year":"2014","unstructured":"Hoogeveen RC, Gaubatz JW, Sun W, et al. Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the Atherosclerosis Risk In Communities (ARIC) study. Arterioscler Thromb Vasc Biol. 2014;34(5):1069\u201377. https:\/\/doi.org\/10.1161\/ATVBAHA.114.303284.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"7","key":"1175_CR14","doi-asserted-by":"publisher","first-page":"669","DOI":"10.5551\/jat.51961","volume":"27","author":"M Higashioka","year":"2020","unstructured":"Higashioka M, Sakata S, Honda T, et al. Small dense low-density lipoprotein cholesterol and the risk of coronary heart disease in a Japanese community. J Atheroscler Thromb. 2020;27(7):669\u201382. https:\/\/doi.org\/10.5551\/jat.51961.","journal-title":"J Atheroscler Thromb."},{"issue":"1","key":"1175_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12933-020-01015-6","volume":"19","author":"JL Jin","year":"2020","unstructured":"Jin JL, Zhang HW, Cao YX, et al. Association of small dense low-density lipoprotein with cardiovascular outcome in patients with coronary artery disease and diabetes: a prospective, observational cohort study. Cardiovasc Diabetol. 2020;19(1):45. https:\/\/doi.org\/10.1186\/s12933-020-01015-6.","journal-title":"Cardiovasc Diabetol."},{"issue":"5","key":"1175_CR16","doi-asserted-by":"publisher","first-page":"e019140","DOI":"10.1161\/JAHA.120.019140","volume":"10","author":"H Ikezaki","year":"2021","unstructured":"Ikezaki H, Lim E, Cupples LA, Liu CT, Asztalos BF, Schaefer EJ. Small dense low-density lipoprotein cholesterol is the most atherogenic lipoprotein parameter in the prospective Framingham offspring study. J Am Heart Assoc. 2021;10(5):e019140. https:\/\/doi.org\/10.1161\/JAHA.120.019140.","journal-title":"J Am Heart Assoc."},{"issue":"7","key":"1175_CR17","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1194\/jlr.R082271","volume":"59","author":"AD Sniderman","year":"2018","unstructured":"Sniderman AD, Couture P, Martin SS, et al. Hypertriglyceridemia and cardiovascular risk: a cautionary note about metabolic confounding. J Lipid Res. 2018;59(7):1266\u201375. https:\/\/doi.org\/10.1194\/jlr.R082271.","journal-title":"J Lipid Res."},{"issue":"17","key":"1175_CR18","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","volume":"362","author":"HN Ginsberg","year":"2010","unstructured":"Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563\u201374. https:\/\/doi.org\/10.1056\/NEJMoa1001282.","journal-title":"N Engl J Med"},{"issue":"21","key":"1175_CR19","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","volume":"387","author":"A Das Pradhan","year":"2022","unstructured":"Das Pradhan A, Glynn RJ, Fruchart JC, et al. Triglyceride lowering with pemafibrate to reduce cardiovascular risk. N Engl J Med. 2022;387(21):1923\u201334. https:\/\/doi.org\/10.1056\/NEJMoa2210645. This trial showed that pemafibrate could not reduce the incidence of cardiovascular events in diabetic patients with dyslipidaemia, despite reducing triglycerides and other lipids, but not apoB.","journal-title":"N Engl J Med."},{"issue":"1","key":"1175_CR20","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","volume":"380","author":"DL Bhatt","year":"2019","unstructured":"Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1812792.","journal-title":"N Engl J Med."},{"issue":"22","key":"1175_CR21","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1001\/jama.2020.22258","volume":"324","author":"SJ Nicholls","year":"2020","unstructured":"Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. Jama. 2020;324(22):2268\u201380. https:\/\/doi.org\/10.1001\/jama.2020.22258.","journal-title":"Jama"},{"issue":"2","key":"1175_CR22","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jacc.2021.04.091","volume":"78","author":"Z Ahmad","year":"2021","unstructured":"Ahmad Z, Pordy R, Rader DJ, et al. Inhibition of angiopoietin-like protein 3 with evinacumab in subjects with high and severe hypertriglyceridemia. J Am Coll Cardiol. 2021;78(2):193\u20135. https:\/\/doi.org\/10.1016\/j.jacc.2021.04.091.","journal-title":"J Am Coll Cardiol."},{"issue":"8","key":"1175_CR23","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa2004215","volume":"383","author":"FJ Raal","year":"2020","unstructured":"Raal FJ, Rosenson RS, Reeskamp LF, et al. Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med. 2020;383(8):711\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2004215.","journal-title":"N Engl J Med"},{"issue":"24","key":"1175_CR24","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa2031049","volume":"383","author":"RS Rosenson","year":"2020","unstructured":"Rosenson RS, Burgess LJ, Ebenbichler CF, et al. Evinacumab in patients with refractory hypercholesterolemia. N Engl J Med. 2020;383(24):2307\u201319. https:\/\/doi.org\/10.1056\/NEJMoa2031049.","journal-title":"N Engl J Med."},{"issue":"6","key":"1175_CR25","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa1715944","volume":"381","author":"JL Witztum","year":"2019","unstructured":"Witztum JL, Gaudet D, Freedman SD, et al. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome. N Engl J Med. 2019;381(6):531\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1715944.","journal-title":"N Engl J Med."},{"issue":"5","key":"1175_CR26","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/S2213-8587(21)00046-2","volume":"9","author":"I Gouni-Berthold","year":"2021","unstructured":"Gouni-Berthold I, Alexander VJ, Yang Q, et al. Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2021;9(5):264\u201375. https:\/\/doi.org\/10.1016\/S2213-8587(21)00046-2.","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"14","key":"1175_CR27","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1093\/eurheartj\/ehab820","volume":"43","author":"JC Tardif","year":"2022","unstructured":"Tardif JC, Karwatowska-Prokopczuk E, Amour ES, et al. Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. Eur Heart J. 2022;43(14):1401\u201312. https:\/\/doi.org\/10.1093\/eurheartj\/ehab820.","journal-title":"Eur Heart J."},{"issue":"12","key":"1175_CR28","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/s41569-021-00569-6","volume":"18","author":"D Montaigne","year":"2021","unstructured":"Montaigne D, Butruille L, Staels B. PPAR control of metabolism and cardiovascular functions. Nat Rev Cardiol. 2021;18(12):809\u201323. https:\/\/doi.org\/10.1038\/s41569-021-00569-6.","journal-title":"Nat Rev Cardiol."},{"issue":"1","key":"1175_CR29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11883-020-00897-x","volume":"23","author":"JC Fruchart","year":"2021","unstructured":"Fruchart JC, Hermans MP, Fruchart-Najib J, Kodama T. Selective peroxisome proliferator-activated receptor alpha modulators (SPPARMalpha) in the metabolic syndrome: is pemafibrate light at the end of the tunnel? Curr Atheroscler Rep. 2021;23(1):3. https:\/\/doi.org\/10.1007\/s11883-020-00897-x.","journal-title":"Curr Atheroscler Rep."},{"issue":"1","key":"1175_CR30","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12944-023-01869-1","volume":"22","author":"L Xiao","year":"2023","unstructured":"Xiao L, Zhang K, Wang F, et al. The LDL-C\/ApoB ratio predicts cardiovascular and all-cause mortality in the general population. Lipids Health Dis. 2023;22(1):104. https:\/\/doi.org\/10.1186\/s12944-023-01869-1.","journal-title":"Lipids Health Dis."},{"issue":"4","key":"1175_CR31","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1001\/jama.2018.20045","volume":"321","author":"BA Ference","year":"2019","unstructured":"Ference BA, Kastelein JJP, Ray KK, et al. Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease. Jama. 2019;321(4):364\u201373. https:\/\/doi.org\/10.1001\/jama.2018.20045.","journal-title":"Jama"},{"key":"1175_CR32","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.atherosclerosis.2016.02.029","volume":"249","author":"S Ishibashi","year":"2016","unstructured":"Ishibashi S, Yamashita S, Arai H, et al. Effects of K-877, a novel selective PPARalpha modulator (SPPARMalpha), in dyslipidaemic patients: a randomized, double blind, active- and placebo-controlled, phase 2 trial. Atherosclerosis. 2016;249:36\u201343. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.02.029.","journal-title":"Atherosclerosis"},{"key":"1175_CR33","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.atherosclerosis.2017.03.032","volume":"261","author":"H Arai","year":"2017","unstructured":"Arai H, Yamashita S, Yokote K, et al. Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor alpha modulator (SPPARMalpha), in combination with statin treatment: two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia. Atherosclerosis. 2017;261:144\u201352. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.03.032.","journal-title":"Atherosclerosis"},{"issue":"1","key":"1175_CR34","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jacl.2017.10.006","volume":"12","author":"S Ishibashi","year":"2018","unstructured":"Ishibashi S, Arai H, Yokote K, et al. Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor alpha modulator, in patients with dyslipidemia: results from a 24-week, randomized, double blind, active-controlled, phase 3 trial. J Clin Lipidol. 2018;12(1):173\u201384. https:\/\/doi.org\/10.1016\/j.jacl.2017.10.006.","journal-title":"J Clin Lipidol."},{"issue":"6","key":"1175_CR35","doi-asserted-by":"publisher","first-page":"521","DOI":"10.5551\/jat.44412","volume":"25","author":"H Arai","year":"2018","unstructured":"Arai H, Yamashita S, Yokote K, et al. Efficacy and safety of pemafibrate versus fenofibrate in patients with high triglyceride and low HDL cholesterol levels: a multicenter, placebo-controlled, double-blind, randomized trial. J Atheroscler Thromb. 2018;25(6):521\u201338. https:\/\/doi.org\/10.5551\/jat.44412.","journal-title":"J Atheroscler Thromb."},{"issue":"9567","key":"1175_CR36","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","volume":"369","author":"M Yokoyama","year":"2007","unstructured":"Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369(9567):1090\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(07)60527-3.","journal-title":"Lancet"},{"issue":"5","key":"1175_CR37","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s40256-023-00593-6","volume":"23","author":"MS Khan","year":"2023","unstructured":"Khan MS, Ghumman GM, Baqi A, et al. Efficacy of pemafibrate versus fenofibrate administration on serum lipid levels in patients with dyslipidemia: network meta-analysis and systematic review. Am J Cardiovasc Drugs. 2023;23(5):547\u201358. https:\/\/doi.org\/10.1007\/s40256-023-00593-6.","journal-title":"Am J Cardiovasc Drugs."},{"issue":"5","key":"1175_CR38","doi-asserted-by":"publisher","first-page":"443","DOI":"10.5551\/jat.63659","volume":"30","author":"A Nakamura","year":"2023","unstructured":"Nakamura A, Kagaya Y, Saito H, et al. Efficacy and safety of pemafibrate versus bezafibrate to treat patients with hypertriglyceridemia: a randomized crossover study. J Atheroscler Thromb. 2023;30(5):443\u201354. https:\/\/doi.org\/10.5551\/jat.63659.","journal-title":"J Atheroscler Thromb."},{"key":"1175_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ahj.2022.11.008","volume":"257","author":"Y Nishizaki","year":"2023","unstructured":"Nishizaki Y, Miyauchi K, Iwata H, et al. Study protocol and baseline characteristics of randomized trial for evaluation in secondary prevention efficacy of combination therapy-statin and eicosapentaenoic acid: RESPECT-EPA, the combination of a randomized control trial and an observational biomarker study. Am Heart J. 2023;257:1\u20138. https:\/\/doi.org\/10.1016\/j.ahj.2022.11.008.","journal-title":"Am Heart J."},{"issue":"5","key":"1175_CR40","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.amjcard.2019.05.057","volume":"124","author":"M Miller","year":"2019","unstructured":"Miller M, Ballantyne CM, Bays HE, et al. Effects of icosapent ethyl (eicosapentaenoic acid ethyl ester) on atherogenic lipid\/lipoprotein, apolipoprotein, and inflammatory parameters in patients with elevated high-sensitivity C-reactive protein (from the ANCHOR study). Am J Cardiol. 2019;124(5):696\u2013701. https:\/\/doi.org\/10.1016\/j.amjcard.2019.05.057.","journal-title":"Am J Cardiol."},{"key":"1175_CR41","doi-asserted-by":"publisher","unstructured":"Gupta A, Alkhalil M. The emerging role of icosapent ethyl in patients with cardiovascular disease: mechanistic insights and future applications. J Clin Med. 2023;12(11) https:\/\/doi.org\/10.3390\/jcm12113758.","DOI":"10.3390\/jcm12113758"},{"issue":"16","key":"1175_CR42","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1161\/CIRCULATIONAHA.119.041998","volume":"140","author":"NA Marston","year":"2019","unstructured":"Marston NA, Giugliano RP, Im K, et al. Association between triglyceride lowering and reduction of cardiovascular risk across multiple lipid-lowering therapeutic classes: a systematic review and meta-regression analysis of randomized controlled trials. Circulation. 2019;140(16):1308\u201317. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.041998.","journal-title":"Circulation"},{"issue":"17","key":"1175_CR43","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1016\/j.jacc.2020.02.059","volume":"75","author":"EK Duran","year":"2020","unstructured":"Duran EK, Aday AW, Cook NR, Buring JE, Ridker PM, Pradhan AD. Triglyceride-rich lipoprotein cholesterol, small dense LDL cholesterol, and incident cardiovascular disease. J Am Coll Cardiol. 2020;75(17):2122\u201335. https:\/\/doi.org\/10.1016\/j.jacc.2020.02.059.","journal-title":"J Am Coll Cardiol."},{"issue":"12","key":"1175_CR44","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1161\/CIRCULATIONAHA.113.003008","volume":"128","author":"A Varbo","year":"2013","unstructured":"Varbo A, Benn M, Tybjaerg-Hansen A, Nordestgaard BG. Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation. Circulation. 2013;128(12):1298\u2013309. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.003008.","journal-title":"Circulation"},{"issue":"2","key":"1175_CR45","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1373\/clinchem.2018.294926","volume":"65","author":"SEJ Hansen","year":"2019","unstructured":"Hansen SEJ, Madsen CM, Varbo A, Nordestgaard BG. Low-grade inflammation in the association between mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis: a study of more than 115000 individuals from the general population. Clin Chem. 2019;65(2):321\u201332. https:\/\/doi.org\/10.1373\/clinchem.2018.294926.","journal-title":"Clin Chem."},{"key":"1175_CR46","doi-asserted-by":"publisher","unstructured":"Bjornson E, Adiels M, Taskinen MR, et al. Triglyceride-rich lipoprotein remnants, low-density lipoproteins, and risk of coronary heart disease: a UK Biobank study. Eur Heart J. 2023; https:\/\/doi.org\/10.1093\/eurheartj\/ehad337.","DOI":"10.1093\/eurheartj\/ehad337"},{"key":"1175_CR47","doi-asserted-by":"publisher","unstructured":"Lawler PR, Akinkuolie AO, Harada P, et al. Residual risk of atherosclerotic cardiovascular events in relation to reductions in very-low-density lipoproteins. J Am Heart Assoc. 2017;6(12) https:\/\/doi.org\/10.1161\/JAHA.117.007402.","DOI":"10.1161\/JAHA.117.007402"},{"issue":"3","key":"1175_CR48","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1612790","volume":"377","author":"FE Dewey","year":"2017","unstructured":"Dewey FE, Gusarova V, Dunbar RL, et al. Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease. N Engl J Med. 2017;377(3):211\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1612790.","journal-title":"N Engl J Med."},{"issue":"16","key":"1175_CR49","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1016\/j.jacc.2017.02.030","volume":"69","author":"NO Stitziel","year":"2017","unstructured":"Stitziel NO, Khera AV, Wang X, et al. ANGPTL3 deficiency and protection against coronary artery disease. JAm Coll Cardiol. 2017;69(16):2054\u201363. https:\/\/doi.org\/10.1016\/j.jacc.2017.02.030.","journal-title":"JAm Coll Cardiol."},{"issue":"1","key":"1175_CR50","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1307095","volume":"371","author":"J Crosby","year":"2014","unstructured":"Crosby J, Peloso GM, Auer PL, et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. 2014;371(1):22\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1307095.","journal-title":"N Engl J Med."},{"issue":"12","key":"1175_CR51","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1093\/eurheartj\/ehaa972","volume":"42","author":"Q Wang","year":"2021","unstructured":"Wang Q, Oliver-Williams C, Raitakari OT, et al. Metabolic profiling of angiopoietin-like protein 3 and 4 inhibition: a drug-target Mendelian randomization analysis. Eur Heart J. 2021;42(12):1160\u20139. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa972.","journal-title":"Eur Heart J."},{"issue":"6","key":"1175_CR52","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1161\/CIRCULATIONAHA.118.039107","volume":"140","author":"Z Ahmad","year":"2019","unstructured":"Ahmad Z, Banerjee P, Hamon S, et al. Inhibition of angiopoietin-like protein 3 with a monoclonal antibody reduces triglycerides in hypertriglyceridemia. Circulation. 2019;140(6):470\u201386. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.039107.","journal-title":"Circulation"},{"issue":"2","key":"1175_CR53","doi-asserted-by":"publisher","first-page":"73","DOI":"10.7555\/JBR.32.20170114","volume":"33","author":"P Tarugi","year":"2019","unstructured":"Tarugi P, Bertolini S, Calandra S. Angiopoietin-like protein 3 (ANGPTL3) deficiency and familial combined hypolipidemia. J Biomed Res. 2019;33(2):73\u201381. https:\/\/doi.org\/10.7555\/JBR.32.20170114.","journal-title":"J Biomed Res."},{"issue":"7","key":"1175_CR54","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1194\/jlr.M054882","volume":"56","author":"Y Wang","year":"2015","unstructured":"Wang Y, Gusarova V, Banfi S, Gromada J, Cohen JC, Hobbs HH. Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion. J Lipid Res. 2015;56(7):1296\u2013307. https:\/\/doi.org\/10.1194\/jlr.M054882.","journal-title":"J Lipid Res."},{"issue":"3","key":"1175_CR55","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41591-023-02222-w","volume":"29","author":"RS Rosenson","year":"2023","unstructured":"Rosenson RS, Gaudet D, Ballantyne CM, et al. Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial. Nat Med. 2023;29(3):729\u201337. https:\/\/doi.org\/10.1038\/s41591-023-02222-w.","journal-title":"Nat Med"},{"issue":"33","key":"1175_CR56","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1093\/eurheartj\/ehz209","volume":"40","author":"VJ Alexander","year":"2019","unstructured":"Alexander VJ, Xia S, Hurh E, et al. N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels. Eur Heart J. 2019;40(33):2785\u201396. https:\/\/doi.org\/10.1093\/eurheartj\/ehz209.","journal-title":"Eur Heart J."},{"issue":"5","key":"1175_CR57","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.jacl.2022.06.005","volume":"16","author":"E Karwatowska-Prokopczuk","year":"2022","unstructured":"Karwatowska-Prokopczuk E, Tardif JC, Gaudet D, et al. Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia. J Clin Lipidol. 2022;16(5):617\u201325. https:\/\/doi.org\/10.1016\/j.jacl.2022.06.005.","journal-title":"J Clin Lipidol."},{"issue":"40","key":"1175_CR58","doi-asserted-by":"publisher","first-page":"3936","DOI":"10.1093\/eurheartj\/ehaa689","volume":"41","author":"D Gaudet","year":"2020","unstructured":"Gaudet D, Karwatowska-Prokopczuk E, Baum SJ, et al. Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia. Eur Heart J. 2020;41(40):3936\u201345. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa689.","journal-title":"Eur Heart J"},{"issue":"18","key":"1175_CR59","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1161\/CIRCULATIONAHA.122.059266","volume":"145","author":"BA Bergmark","year":"2022","unstructured":"Bergmark BA, Marston NA, Bramson CR, et al. Effect of vupanorsen on non-high-density lipoprotein cholesterol levels in statin-treated patients with elevated cholesterol: TRANSLATE-TIMI 70. Circulation. 2022;145(18):1377\u201386. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.059266.","journal-title":"Circulation"},{"issue":"9","key":"1175_CR60","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1038\/s41591-023-02494-2","volume":"29","author":"GF Watts","year":"2023","unstructured":"Watts GF, Schwabe C, Scott R, et al. RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts. Nat Med. 2023;29(9):2216\u201323. https:\/\/doi.org\/10.1038\/s41591-023-02494-2.","journal-title":"Nat Med."},{"key":"1175_CR61","doi-asserted-by":"publisher","unstructured":"Schwabe C, Scott R, Sullivan D, et al. RNA interference targeting apolipoprotein C-III with ARO-APOC3 in healthy volunteers mimics lipid and lipoprotein findings seen in subjects with inherited apolipoprotein C-III deficiency. Eur Heart J. 2020;41(Supplement_2) https:\/\/doi.org\/10.1093\/ehjci\/ehaa946.3330.","DOI":"10.1093\/ehjci\/ehaa946.3330"},{"issue":"Suppl_1","key":"1175_CR62","doi-asserted-by":"publisher","first-page":"A10357","DOI":"10.1161\/circ.144.suppl_1.10357","volume":"144","author":"P Clifton","year":"2021","unstructured":"Clifton P, Sullivan D, Baker J, et al. Abstract 10357: ARO-APOC3, an investigational RNAi therapeutic, shows similar efficacy and safety in genetically confirmed FCS and non-FCS participants with severe hypertriglyceridemia. Circulation. 2021;144(Suppl_1):A10357. https:\/\/doi.org\/10.1161\/circ.144.suppl_1.10357.","journal-title":"Circulation"},{"issue":"3","key":"1175_CR63","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s11883-022-00994-z","volume":"24","author":"CJ Packard","year":"2022","unstructured":"Packard CJ. Remnants, LDL, and the quantification of lipoprotein-associated risk in atherosclerotic cardiovascular disease. Curr Atheroscler Rep. 2022;24(3):133\u201342. https:\/\/doi.org\/10.1007\/s11883-022-00994-z.","journal-title":"Curr Atheroscler Rep."},{"issue":"1","key":"1175_CR64","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455.","journal-title":"Eur Heart J."},{"issue":"3","key":"1175_CR65","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.jacl.2023.03.007","volume":"17","author":"JL Witztum","year":"2023","unstructured":"Witztum JL, Gaudet D, Arca M, et al. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial. J Clin Lipidol. 2023;17(3):342\u201355. https:\/\/doi.org\/10.1016\/j.jacl.2023.03.007.","journal-title":"J Clin Lipidol."},{"issue":"16","key":"1175_CR66","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/j.jacc.2023.02.034","volume":"81","author":"WA Malick","year":"2023","unstructured":"Malick WA, Waksman O, Do R, et al. Clinical trial design for triglyceride-rich lipoprotein-lowering therapies: JACC Focus Seminar 3\/3. J Am Coll Cardiol. 2023;81(16):1646\u201358. https:\/\/doi.org\/10.1016\/j.jacc.2023.02.034. This review provides possible reasons for the failure of clinical trials assessing TG-lowering therapies.","journal-title":"J Am Coll Cardiol."}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-023-01175-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-023-01175-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-023-01175-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T06:43:08Z","timestamp":1704436988000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-023-01175-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":66,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["1175"],"URL":"https:\/\/doi.org\/10.1007\/s11883-023-01175-2","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"18 November 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AP has nothing to disclose. ALC has received honoraria, lecture fees or research grants from Aegerion, Amgen, Amryt, AstraZeneca, Bayer, Daiichi-Sankyo, Eli Lilly, Genzyme, Ionis Pharmaceutical, Kowa, Mediolanum, Medscape, Menarini, Merck, Mylan, Novartis, PeerVoice, Pfizer, Recordati, Regeneron, Sanofi, Sigma-Tau and The Corpus, outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}